Psychotomimesis Mediated by κ Opiate Receptors
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The κ opioid agonists are analgesics that seem to be free of undesired morphine-like effects. Their dysphoric actions observed with the κ agonist cyclazocine are thought to be mediated by an action at σ-phencyclidine receptors. The benzomorphan κ agonist MR 2033 is inactive at σ-phencyclidine receptors. In male subjects, the opiate-active (-)-isomer, but not the (+)-isomer, elicited dose-dependent dysphoric and psychotomimetic effects that were antagonized by naloxone. Thus, κ opiate receptors seem to mediate psychotomimetic effects. In view of the euphorigenic properties of μ agonists, our results imply the existence of opposed opioid systems affecting emotional and perceptual experiences.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“agonism of κ-opioid receptors were shown to produce depression-like symptoms in humans (Pfeiffer et al., 1986).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Pfeiffer et al., 1986
In the citing paper
“Nonetheless, the three receptor types have different behavioral domains, with MOR and DOR mediating generally positive motivation and affect, while KOR mediates generally negative motivation and aversion (Pfeiffer et al 1986; Shippenberg et al 1987; Pecina and Berridge 2000; McLaughlin et al 2003; for reviews see Van Ree et al 2000; Le Merrer et al 2009).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Pfeiffer et al 1986
In the citing paper
“Kappa receptor agonists induce anxiogenic and dysphoric effects in humans (141-143) and depressive-like behavior in animals (i.e., increased immobility in the forced swim test) (144, 145).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [141]
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man
Domino, E. F., Chodoff, P., & Corssen, G. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563279 · Cited by 748
Martin, W. R. (1983) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06637-2 · Cited by 648
Thrills in response to music and other stimuli
Goldstein, A. (1980) · Physiological Psychology · doi:10.3758/bf03326460 · Cited by 522
Mucha, R. F., & Herz, A. (1985) · Psychopharmacology · doi:10.1007/bf00432213 · Cited by 510
Self-citationThe binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties
Magnan, J., Paterson, S. J., Tavani, A., & Kosterlitz, H. W. (1982) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00495865 · Cited by 509
A CLASSIFICATION OF OPIATE RECEPTORS THAT MEDIATE ANTINOCICEPTION IN ANIMALS
TYERS, M. B. (1980) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1980.tb07041.x · Cited by 341
Opiate receptor binding sites in human brain
Pfeiffer, A., Pasi, A., Mehraein, P., & Herz, A. (1982) · Brain Research · doi:10.1016/0006-8993(82)91150-7 · Cited by 298
Self-citationPhencyclidine (angel dust)/sigma "opiate" receptor: visualization by tritium-sensitive film.
Quirion, R., Hammer, R. P., Herkenham, M., & Pert, C. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5881 · Cited by 254
Research works printed but not linked: 6
- Jasinski, D. R., Drug Addiction 1: 216 (1977).
- MARTIN, W.R., PHARMACOL REV 35: 283 (1984).
- MARTIN, W.R., SUBSTANCE AND ALCOHOL ACTIONS/MISUSE 1: 269 (1980).
- Shearman, G. T., Drug Discrimination: Application in CNS Pharmacology: 37 (1982).
- VAUPEL, D.B., FAILURE OF NALTREXONE (NTX) TO ANTAGONIZE PHENCYCLIDINE (PCP) AND THE OPIOID SKF-10047 (SKF) IN THE DOG, FEDERATION PROCEEDINGS 41: 1333 (1982).
- Zerssen, D. V., Assessment of Depression: 270 (1985).
Cited by
Items 501–600 of 956
Cyclic Endomorphin Analogs in Targeting Opioid Receptors to Achieve Pain Relief
Janecka, A. E., & Gentilucci, L. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.132 · Cited by 20
Wang, Q., Long, Y., Hang, A., Zan, G., Shu, X. H., Wang, Y., & Liu, J. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4292-z · Cited by 20
Chemical syntheses of the salvinorin chemotype of KOR agonist
Hill, S. J., Brion, A., & Shenvi, R. A. (2020) · Natural Product Reports · doi:10.1039/d0np00028k · Cited by 20
Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine
Cameron, C. M., Nieto, S. J., Bosler, L., Wong, M. H., Bishop, I., Mooney, L. J., & Cahill, C. M. (2021) · Advances in Drug and Alcohol Research · doi:10.3389/adar.2021.10009 · Cited by 20
Dynorphin a Analogs for the Treatment of Chronic Neuropathic Pain
Hall, S. M., Lee, Y. S., & Hruby, V. J. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc.15.164 · Cited by 20
Opioid-dependent regulation of high and low fear responses in two inbred mouse strains
Szklarczyk, K., Korostyński, M., Cieślak, P. E., Wawrzczak‐Bargieła, A., & Przewłocki, R. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.06.001 · Cited by 20
Shannon, H. E., Eberle, E. L., Mitch, C. H., McKinzie, D. L., & Statnick, M. A. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.09.002 · Cited by 20
Stevenson, G. W., Wentland, M. P., Bidlack, J. M., Mello, N. K., & Negus, S. S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.10.051 · Cited by 20
Wang, Y., Li, J., Huang, P., Xu, W., & Liu‐Chen, L. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055814 · Cited by 20
Low efficacy opioids: Implications for sex differences in opioid antinociception.
Barrett, A. C. (2006) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.14.1.1 · Cited by 20
Reid, A. A., Mattson, M. V., COSTA, B. R. D., Thurkauf, A., Jacobson, A. E., Monn, J. A., Rice, K. C., & Rothman, R. B. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90154-j · Cited by 20
Aldrich, J. V., & Vigil‐Cruz, S. C. (2003) · Wiley eBooks · doi:10.1002/0471266949.bmc100 · Cited by 20
McCurdy, C. R., & Prisinzano, T. E. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc251 · Cited by 20
Opioid modulation of prefrontal cortex cells and circuits
Cole, R. H., Moussawi, K., & Joffe, M. E. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109891 · Cited by 19
Cohen, A., Whitfield, T. W., Kreifeldt, M., Koebel, P., Kieffer, B. L., Contet, C., George, O., & Koob, G. F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097216 · Cited by 19
Ketamine plus Alcohol: What We Know and What We Can Expect about This
Kobayashi, N. H. C., Farias, S. V., Luz, D. A., Ferraro, K. M. M. M., da Conceição, B. C., da Silveira, C. C. S. D. M., Fernandes, L. M. P., Cartágenes, S. D. C., Ferreira, V. M. M., Fontes-Júnior, E. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147800 · Cited by 19
Salvia divinorum: A Psychopharmacological Riddle and a Mind-Body Prospect
Diaz, J.-L. (2013) · Current Drug Abuse Reviews · doi:10.2174/18744737112059990004 · Cited by 19
In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor
Casal-Dominguez, J. J., Clark, M. J., Traynor, J. R., Husbands, S. M., & Bailey, S. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112464828 · Cited by 19
Zhang, H., Wang, F., Kranzler, H. R., Anton, R. F., & Gelernter, J. E. (2012) · Behavioral and Brain Functions · doi:10.1186/1744-9081-8-23 · Cited by 19
Contribution of Dynorphin and Orexin Neuropeptide Systems to the Motivational Effects of Alcohol
Anderson, R. I., Moorman, D. E., & Becker, H. C. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_100 · Cited by 19
Brice‐Tutt, A. C., Senadheera, S. N., Ganno, M. L., Eans, S. O., Khaliq, T., Murray, T. F., McLaughlin, J. P., & Aldrich, J. V. (2020) · Molecules · doi:10.3390/molecules25173999 · Cited by 19
Biased Ligands at the Kappa Opioid Receptor: Fine-Tuning Receptor Pharmacology
Brust, T. F. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_395 · Cited by 19
Dynorphin/Kappa-Opioid Receptor System Modulation of Cortical Circuitry
Tejeda, H. A., Wang, H., Flores, R. J., & Yarur, H. E. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_440 · Cited by 19
Kappa opioid receptors mediate where fear is expressed following extinction training
Cole, S., Richardson, R., & McNally, G. P. (2011) · Learning & Memory · doi:10.1101/lm.2049511 · Cited by 19
Fichna, J., Schicho, R., Janecka, A. E., Zjawiony, J. K., & Storr, M. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.7.1400219 · Cited by 19
A highly selective κ-opioid receptor agonist with low addictive potential and dependence liability
Park, H. S., Lee, H. Y., Kim, Y. H., Park, J. K., Zvartau, E. E., & Lee, H. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.02.017 · Cited by 19
Zan, G., Wang, Q., Wang, Y.-J., Chen, J.-C., Wu, X. L., Yang, C., Chai, J., Li, M., Liu, Y., Hu, X., et al. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.01.052 · Cited by 18
Shahkarami, K., Vousooghi, N., Golab, F., Mohsenzadeh, A., Baharvand, P., Sadat‐Shirazi, M., Babhadi‐Ashar, N., Shakeri, A., & Zarrindast, M. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107638 · Cited by 18
Learned avoidance requires VTA KOR-mediated reductions in dopamine
Robble, M. A., Bozsik, M., Wheeler, D. S., & Wheeler, R. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107996 · Cited by 18
Kappa Opioid Receptor Function
Lemos, J. C., & Chavkin, C. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-993-2_11 · Cited by 18
Operant Assays for Assessing Pain in Preclinical Rodent Models: Highlights from an Orofacial Assay
Murphy, N. P., Mills, R. H., Caudle, R. M., & Neubert, J. K. (2014) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_332 · Cited by 18
Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models
Yoshikawa, S., Hareyama, N., Ikeda, K., Kurokawa, T., Nakajima, M., Nakao, K., Mochizuki, H., & Ichinose, H. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.01.043 · Cited by 18
Vonkeman, H. E., Voorn, P., Brady, L. S., Berendse, H. W., & Richfield, E. K. (1996) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19961014)374:2<223::aid-cne5>3.0.co;2-4 · Cited by 18
Ni, Q., Xu, H., Partilla, J. S., de Costa, B. R., Rice, K. C., Kayakiri, H., & Rothman, R. B. (1995) · Peptides · doi:10.1016/0196-9781(95)00091-w · Cited by 18
GPCR‐G protein selectivity revealed by structural pharmacology
Bernhard, S. M., Han, J., & Che, T. (2023) · FEBS Journal · doi:10.1111/febs.17049 · Cited by 17
Analgesic Peptides: From Natural Diversity to Rational Design
Gach, K., Biernat, M., Kuczer, M., Adamska‐Bartłomiejczyk, A., & Kluczyk, A. (2024) · Molecules · doi:10.3390/molecules29071544 · Cited by 17
Hypocretin/Orexin and Plastic Adaptations Associated with Drug Abuse
Baimel, C., & Borgland, S. L. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_44 · Cited by 17
GPCR and Alcohol-Related Behaviors in Genetically Modified Mice
Neasta, J., Darcq, E., Jeanblanc, J., Carnicella, S., & Hamida, S. B. (2020) · Neurotherapeutics · doi:10.1007/s13311-019-00828-y · Cited by 17
Characterization of BU09059: A Novel Potent Selective κ-Receptor Antagonist
Casal-Dominguez, J. J., Furkert, D. P., Ostovar, M., Teintang, L., Clark, M. J., Traynor, J. R., Husbands, S. M., & Bailey, S. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn4001507 · Cited by 17
Huang, P., Yakovleva, T., Aldrich, J. V., Tunis, J., Parry, C., & Liu‐Chen, L. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.01.017 · Cited by 17
Minervini, V., Lu, H., Padarti, J., Osteicoechea, D. C., & France, C. P. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4920-x · Cited by 17
Margolis, E. B., Wallace, T. L., Orden, L. J. V., & Martin, W. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232864 · Cited by 17
Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development
Aldrich, J. V., & McLaughlin, J. P. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_519 · Cited by 17
Huang, P., Chen, C., Cao, D., Huang, M., & Liu‐Chen, L. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108860 · Cited by 17
The endogenous opioid dynorphin is required for normal bone homeostasis in mice
Baldock, P. A. J., Drießler, F., Lin, S., Wong, I. P. L., Shi, Y., Yulyaningsih, E., Castillo, L. E., Janmaat, S., Enriquez, R. F., Zengin, A., et al. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.08.010 · Cited by 17
Opioid and nondopamine reward circuitry and state‐dependent mechanisms
Fujita, M., Ide, S., & Ikeda, K. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13605 · Cited by 17
Reyes, B. A. S., Chavkin, C., & Bockstaele, E. J. V. (2010) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2010.09.003 · Cited by 17
Effects of morphine on brain-stimulation reward thresholds in young and aged rats
Jha, S. H., Knapp, C. M., & Kornetsky, C. H. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.08.014 · Cited by 17
Characterization of kappa1-opioid receptor binding in human insular cortex
Izenwasser, S., Staley, J. K., Cohn, S., & Mash, D. C. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00315-x · Cited by 17
The κ-opioid receptor agonist U50,488H induces acute physical dependence in guinea-pigs
Brent, P. J., Chahl, L. A., Pa, C., & Kavanagh, C. A. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90196-o · Cited by 17
A review of the kappa opioid receptor system in opioid use
Çayır, S., Zhornitsky, S., Barzegary, A., Carreño, E. S., Sarfo-Ansah, W., Funaro, M. C., Matuskey, D., & Angarita, G. A. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105713 · Cited by 16
Opioid-receptor antagonism increases pain and decreases pleasure in obese and non-obese individuals
Price, R. C., Christou, N. V., Backman, S. B., Stone, L. S., & Schweinhardt, P. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4417-4 · Cited by 16
Heinsbroek, J. A., Furbish, A. B., & Peters, J. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-017-0006-4 · Cited by 16
Effects of Combined Opioids on Pain and Mood in Mammals
Rech, R. H., Mokler, D. J., & Briggs, S. L. (2012) · Pain Research and Treatment · doi:10.1155/2012/145965 · Cited by 16
Predicted Structures for Kappa Opioid G-Protein Coupled Receptor Bound to Selective Agonists
Li, Q., Kim, S., Goddard, W. A., Chen, G., & Tan, H. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci500523z · Cited by 16
El‐Khoury, J., & Sahakian, N. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1073815 · Cited by 16
Yi, S.-P., Kong, Q., Li, Y., Pan, C., Yu, J., Cui, B., Wang, Y., Wang, G., Zhou, P., Wang, L.-L., et al. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.14 · Cited by 16
Shu, H., Hayashida, M., Huang, W., An, K., Chiba, S., Hanaoka, K., & Arita, H. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.01.029 · Cited by 16
New therapeutic potential for psychoactive natural products
Prevatt‐Smith, K. M., & Prisinzano, T. E. (2009) · Natural Product Reports · doi:10.1039/b912196j · Cited by 16
Treatment of alcohol dependence with drug antagonists of the stress response
Higley, A. E., Koob, G. F., & Mason, B. J. (2012) · Alcohol research · doi:10.35946/arcr.v34.4.15 · Cited by 16
Chapter 6. Translational Research Issues In Dissociation
Schmahl, C. G., & Bohus, M. (2007) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615377503.lg06 · Cited by 16
Magnusson, K. A., Birgner, C., Bergström, L., Nyberg, F., & Hallberg, M. (2009) · Neuropeptides · doi:10.1016/j.npep.2008.12.005 · Cited by 16
Patkar, K. A., Murray, T. F., & Aldrich, J. V. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900715m · Cited by 16
Nicotine withdrawal and κ-opioid receptors
McCarthy, M. J., Zhang, H., Neff, N. H., & Hadjiconstantinou, M. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1674-5 · Cited by 16
Molecular Adaptations to Psychostimulants in Striatal Neurons: Toward a Pathophysiology of Addiction
Genova, L. M., Berke, J. D., & Hyman, S. E. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0154 · Cited by 16
Soares, J. A. G., Sutley-Koury, S. N., Pomrenze, M. B., & Tucciarone, J. (2025) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2024.1521016 · Cited by 15
Mathew, S. J., Cutler, A. J., Visitacion, N. C., Gold, M., Yuan, J. X. ‐., & Aurora, B. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001967 · Cited by 15
Wallace, T., Martin, W. J., & Arnsten, A. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100493 · Cited by 12
Focus on: Neuroscience and treatment: the potential of neuroscience to inform treatment.
Koob, G. F. (2010) · Alcohol Research & Health · Cited by 15
Yoshizawa, K., Narita, M., Saeki, M., Narita, M., Isotani, K., Horiuchi, H., Imai, S., Kuzumaki, N., & Suzuki, T. (2011) · Synapse · doi:10.1002/syn.20937 · Cited by 15
Townsend, E. A. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05749-9 · Cited by 15
Kappa Opioid Signaling at the Crossroads of Chronic Pain and Opioid Addiction
Cahill, C. M., Lueptow, L. M., Kim, H., Shusharla, R., Bishop, A., & Evans, C. J. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_434 · Cited by 15
Effects of Opioids on the Spontaneous Behavior of Animals
Cowan, A. (1993) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-77540-6_16 · Cited by 15
Opioids in the Etiology and Treatment of Psychiatric Disorders
Naber, D. (1993) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-77540-6_32 · Cited by 15
Huang, P., Ho, C. K., Cao, D., Inan, S., Rawls, S. M., Li, M., Huang, B., Pagare, P. P., Townsend, E. A., Poklis, J. L., et al. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001870 · Cited by 14
Meariman, J. K., Sutphen, J. C., Gao, J., & Kapusta, D. R. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.18503 · Cited by 14
Discovery of Peripheral κ-Opioid Receptor Agonists as Novel Analgesics
Suzuki, S., Sugawara, Y., Inada, H., Tsuji, R., Inoue, A., Tanimura, R., Shimozono, R., Konno, M., Ohyama, T., Higashi, E., et al. (2017) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c17-00555 · Cited by 14
Hruby, V. J. (2019) · Peptides · doi:10.1016/j.peptides.2019.02.004 · Cited by 14
Pain, Motivation, Migraine, and the Microbiome: New Frontiers for Opioid Systems and Disease
Parker, K. E., Sugiarto, E., Taylor, A. M. W., Pradhan, A. A. A., & Al‐Hasani, R. (2020) · Molecular Pharmacology · doi:10.1124/mol.120.119438 · Cited by 14
Schmidhammer, H., Erli, F., Guerrieri, E., & Spetea, M. (2020) · Molecules · doi:10.3390/molecules25215092 · Cited by 14
Jamshidi, R. J., Sullivan, L. C., Jacobs, B. A., Chavera, T. A., Berg, K. A., & Clarke, W. P. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235184 · Cited by 14
Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles
Ioja, E., Tourwé, D., Kertész, I., Tóth, G., Borsodi, A. D., & Benyhe, S. (2007) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2007.05.010 · Cited by 14
Implications of the multiplicity of opioid receptors for the problem of addiction
Herz, A. (1990) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(90)90050-o · Cited by 14
Self-citationVIRAL AND CELLULAR DETERMINANTS OF APOPTOSIS INDUCED BY MAMMALIAN REOVIRUS
O'donnell, S., Hansberger, M. W., & Dermody, T. S. (2003) · International Reviews of Immunology · doi:10.1080/08830180305212 · Cited by 14
The Effects of Transnasal Butorphanol on Mood and Psychomotor Functioning in Healthy Volunteers
Zacny, J. P., Lichtor, J. L., Klafta, J. M., Alessi, R., & Apfelbaum, J. L. (1996) · Anesthesia & Analgesia · doi:10.1097/00000539-199605000-00007 · Cited by 14
Silberstein, S., & McCrory, D. (2000) · Cephalalgia · doi:10.1046/j.1468-2982.2000.00149.x · Cited by 14
PAIN MANAGEMENT IN THE PEDIATRIC INTENSIVE CARE UNIT
Macfadyen, A. J., & Buckmaster, M. A. (1999) · Critical Care Clinics · doi:10.1016/s0749-0704(05)70047-6 · Cited by 14
G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics
Schmitz, G. P., & Roth, B. L. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00397.2022 · Cited by 13
Gach, K., Piekielna‐Ciesielska, J., Adamska‐Bartłomiejczyk, A., Wtorek, K., Ferrari, F., Calò, G., Szymaszkiewicz, A., Piasecka‐Zelga, J., & Janecka, A. E. (2018) · Peptides · doi:10.1016/j.peptides.2018.04.014 · Cited by 13
Flores‐Ramirez, F. J., Illenberger, J. M., Pascasio, G., Terenius, L. Y., & Martin‐Fardon, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-56500-9 · Cited by 13
Trojniak, A. E., Dang, V. Q., Czekner, K. M., Russo, R. J., Mather, L. M., Stahl, E. L., Cameron, M. D., Bohn, L., & Aubé, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116627 · Cited by 13
Control of synaptic transmission and neuronal excitability in the parabrachial nucleus
Cramer, N., Silva-Cardoso, G. K., Masri, R. M., & Keller, A. (2020) · Neurobiology of Pain · doi:10.1016/j.ynpai.2020.100057 · Cited by 13
Spetea, M., & Schmidhammer, H. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2020_431 · Cited by 13
Synthesis and Assessment of Fused β‐Carboline Derivatives as Kappa Opioid Receptor Agonists
Yadav, V. D., Kumar, L., Kumari, P., Kumar, S., Singh, M., Siddiqi, M. I., Yadav, P. N., & Batra, S. (2021) · ChemMedChem · doi:10.1002/cmdc.202100029 · Cited by 13
Tracking Down the Molecular Substrates of Stress: New Roles for p38α MAPK and Kappa-Opioid Receptors
Muschamp, J. W., Veer, A. V., & Carlezon, W. A. (2011) · Neuron · doi:10.1016/j.neuron.2011.07.018 · Cited by 13
Opioid and hypocretin neuromodulation of ventral tegmental area neuronal subpopulations
Thomas, T. S., Baimel, C., & Borgland, S. L. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13993 · Cited by 13
CREB involvement in the regulation of striatal prodynorphin by nicotine
McCarthy, M. J., Duchemin, A., Neff, N. H., & Hadjiconstantinou, M. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2559-y · Cited by 13
Ableitner, A., & Herz, A. (1989) · Brain Research · doi:10.1016/0006-8993(89)91513-8 · Cited by 13
Self-citationPearl, S. M., & Glick, S. D. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12822-6 · Cited by 13
Gregg, R. V. (1989) · Anesthesiology Clinics of North America · doi:10.1016/s0889-8537(21)00224-8 · Cited by 13
Metadata
- Authors
- Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M.
- Affiliations
- LMU Klinikum (DE)
- Boehringer Ingelheim (Germany) (DE)
- Max Planck Society (DE)
- Max Planck Institute of Psychiatry (DE)
- ORCID
- Pfeiffer, Andreas
- Venue
- Science
- Published
- 1986-08-15
- Volume
- 233
- Issue
- 4765
- Pages
- 774-776
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2032643119
- Cited by
- 857
- References
- 30
- Citations by year
- 2026: 20 · 2025: 19 · 2024: 23 · 2023: 17 · 2022: 18 · 2021: 38 · 2020: 42 · 2019: 21 · 2018: 27 · 2017: 24 · 2016: 37 · 2015: 38 · 2014: 30 · 2013: 35 · 2012: 41
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- psychotomimetic effects, kappa opioid receptor, kappa opioid receptor agonists, cyclazocine, naloxone antagonism, stereoisomers, mu-opioid receptor agonists, euphoria, analgesia
- MeSH terms
- Adult, Anxiety, Benzomorphans, Humans, Male, Middle Aged, Morphinans, Naloxone, Personality Tests, Phencyclidine, Receptors, Opioid, Receptors, Opioid, kappa
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.